Longer antifungal course protects against chronic pulmonary aspergillosis relapse

Review of current treatment guidelines is warranted, researchers say
Reuters Health
Microscope view of the mycelium of Aspergillus fumigatus.

A year-long course of itraconazole is superior to a six-month course at reducing relapses of chronic pulmonary aspergillosis at two years, new research suggests.

Although most guidelines recommend at least six months of antifungal therapy for the condition — typically caused by Aspergillus fumigatus — clinicians say the optimal duration of treatment remains unclear.